NasdaqCM - Nasdaq Real Time Price USD

ProPhase Labs, Inc. (PRPH)

Compare

0.6055

-0.0345

(-5.39%)

At close: 4:00:00 PM EST

0.5760

-0.03

(-4.87%)

After hours: 4:11:23 PM EST

ProPhase Labs Secures Global Private Equity Backing, Nears Major Lozenge Deal, Adds Seasoned Industry Expert, and Plans Significant Cost-Cutting Measures

The Company will review on Thursday, December 12th, at 12:00 p.m. EST. GARDEN CITY, NY, Dec. 11, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today provided updates on several key initiatives. Securing Low-Interest Rate Financing from a Global Private Equity Fund ProPhase has secured an agreement with a billion-dollar global private equity fund, providing flexible, low-interest rate debt f

GlobeNewswire last month

PRPH
-5.39%
Impact BioMedical Inc. Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision

HOUSTON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that Frank D. Heuszel, Chairman and Chief Executive Officer of Impact BioMedical Inc., issued the following letter to Impact BioMedical shareholders regarding recent achievements, executional efficiencies and the positive outlook for the Company’s future. Dear Impact Biomedic

GlobeNewswire last month

IBO

PRPH
-5.39%
ProPhase Labs Inc (PRPH) Q3 2024 Earnings Call Highlights: Strategic Launches and Financial ...

ProPhase Labs Inc (PRPH) outlines aggressive product launches and cost-cutting measures while addressing significant accounts receivable issues.

GuruFocus.com last month

PRPH
-5.39%
Diamond Equity Research Releases Update Note on ProPhase Labs Inc. (NASDAQ: PRPH)

New York, NY, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, an equity research firm with a focus on small capitalization public companies has released an Update Note on ProPhase Labs Inc. (NASDAQ: PRPH). The update note includes information on ProPhase’s business model, services offered, industry outlook, financial results, management commentary, valuation, and risks. The update note is available below. ProPhase Labs November 2024 Update Note Highlights from the note include: Launch

GlobeNewswire last month

PRPH
-5.39%
ProPhase Labs, Inc. (PRPH) Reports Q3 Loss, Tops Revenue Estimates

ProPhase Labs (PRPH) delivered earnings and revenue surprises of -12.90% and 11.56%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

PRPH
-5.39%
PSTV
ProPhase Labs Announces Financial Results for the Three Months Ended September 30, 2024

Highlights Q4 2024 and Q1 2025 with multiple potential liquidity events, growth in multiple subsidiaries as well as potentially significant reduction in overhead and expenses Company to hold a virtual conference call Wednesday, November 13, 2024, at 11:00 AM ET GARDEN CITY, NY, Nov. 13, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today reported its financial and operational results for th

GlobeNewswire 2 months ago

PRPH
-5.39%
ProPhase Labs Announces Closing of Public Offering of Common Stock

GARDEN CITY, NY, Nov. 12, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics and diagnostics company, today announced the closing of its previously announced underwritten public offering of 4,795,500 shares of its common stock, including 625,500 shares sold upon full exercise of the underwriter's option to purchase additional shares. Each share of common stock was sold at a public offering price of $0.72 per share, for g

GlobeNewswire 2 months ago

PRPH
-5.39%
ProPhase Labs Inc. to Present Third Quarter 2024 Financial Results on November 13, 2024

GARDEN CITY, NY, Nov. 11, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and diagnostics company, today announced that they will be presenting third quarter 2024 financial results on a virtual conference call hosted by Renmark Financial on November 13, 2024 at 11:00 AM EST. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors,

GlobeNewswire 2 months ago

PRPH
-5.39%
Top Midday Decliners

Top Midday Decliners

PREMIUM
MT Newswires 2 months ago

MRVI

PRPH
-5.39%
EVH
ProPhase Labs Announces Pricing of Public Offering of Common Stock

GARDEN CITY, NY, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics and diagnostics company, today announced the pricing of its underwritten public offering of 4,170,000 shares of common stock. Each share of common stock is being sold at a public offering price of $0.72 per share, for gross proceeds of approximately $3 million, before deducting underwriting discounts, and offering expenses. All of the shares are

GlobeNewswire 2 months ago

PRPH
-5.39%
ProPhase Labs Announces Proposed Public Offering of Common Stock

GARDEN CITY, NY, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next-generation biotech, genomics and diagnostics company, today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof) in an underwritten public offering. The Company expects to grant the underwriters a 45-day option to purchase up to an additional 15% of the number of shares of common stock and/or Pre-Funded Warrants sold i

GlobeNewswire 2 months ago

PRPH
-5.39%
ProPhase Labs Launches DNA Complete®: Transforming Direct-to-Consumer Genetic Testing for Health, Wellness, and Enhanced Ancestry

Introduces DNA Expand Subscription Platform to Enrich Existing DNA Ancestry Data with Comprehensive Health Insights GARDEN CITY, NY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics, and diagnostics company, today announced the launch of DNA Complete, Inc., a wholly owned subsidiary, offering a groundbreaking direct-to-consumer DNA test that sequences virtually 100% of a customer’s genome. This new service pro

GlobeNewswire 2 months ago

PRPH
-5.39%
ProPhase Labs to Present at the 2024 ThinkEquity Conference

GARDEN CITY, NY, Oct. 22, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics, and diagnostics company, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. Past ThinkEquity conferences have featured over 70 company presentations, 700+ attendees, and 500+ one-on-one meetings, providing a valuable platform for companies and investors to

GlobeNewswire 2 months ago

PRPH
-5.39%
ProPhase Labs Announces Positive Updates on Strategic Initiatives Company Anticipates Multiple Liquidity Events in H1 2025

Projections for Pharmaloz Manufacturing: Approximately $16-17 Million in Revenue, $6-7 Million in Pre-Tax Earnings for 2025 Strategic Partnership Discussions Begin for BE-Smart Esophageal Cancer Test GARDEN CITY, NY, Oct. 17, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics, and diagnostics company, today announced significant progress across several key projects. Pharmaloz Manufacturing Inc. (PMI): In Q3, the Company

GlobeNewswire 2 months ago

PRPH
-5.39%
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing

NEW YORK, NY / ACCESSWIRE / September 11, 2024 / Investor Summit Group, an independent organization focused on creating networking opportunities for the MicroCap and SmallCap community, has announced that presentations from the August 20 Microcap ...

ACCESSWIRE 4 months ago

DCGO

SOTK

CVKD
ProPhase Labs to Present at August 20th Virtual Investor Summit Microcap Event

GARDEN CITY, NY, Aug. 19, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today announced that it will be presenting at the Virtual Investor Summit Microcap Event. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation. Event: Q3 Investor SummitDate: August 20th, 2024Presentation Time: 1:00 P.M. ET Location: https://www.webcaster4.com/Webcast/Pa

GlobeNewswire 4 months ago

PRPH
-5.39%
ProPhase Labs Announces Financial Results for the Three Months Ended June 30, 2024

Company Anticipates Significant Sequential Growth in Quarterly Revenues Beginning in Q3 2024 and Beyond Reports Pharmaloz Growth Acceleration Has Begun in Q3 2024 and Potential Sale of Business Announces Major DTC Initiatives for Nebula Genomics, anticipating new sales ramp in Q4 2024 Company to hold a virtual conference call Wednesday, August 14, 2024, at 11:00 AM ET GARDEN CITY, NY, Aug. 14, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-gener

GlobeNewswire 4 months ago

PRPH
-5.39%
ProPhase Labs Announces Collaboration with Forward Healthcare Consultants to Aid in the Commercialization of its Billion Dollar Potential BE-Smart Esophageal Cancer Test

GARDEN CITY, NY, Aug. 13, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next-generation biotech, genomics, and diagnostics company, today reported its collaboration with Forward Healthcare Consultants (FHC) to bring its BE-Smart test for esophageal cancer to market. The experts at FHC will assist with securing market access by focusing on clinical validation and commercialization planning, to include coverage, pricing, and coding. Additionally, FHC will bring its vast relationsh

GlobeNewswire 4 months ago

PRPH
-5.39%
PROPHASE LABS INC. TO PRESENT SECOND QUARTER 2024 FINANCIAL RESULTS ON AUGUST 14

GARDEN CITY, NY, Aug. 07, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), announced today that they will be presenting second quarter 2024 financial results on a virtual conference call hosted by Renmark Financial on August 14, 2024 at 11:00 am EDT. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event. Investors interested

GlobeNewswire 5 months ago

PRPH
-5.39%
ProPhase Labs Announces Update on Pharmaloz Manufacturing, Inc. Progress

PMI Revenues and Earnings Projected to Grow Significantly in the Second Half of 2024 and Full Year 2025. New Strategic Initiatives for PMI Create Significant Opportunities for Liquidity and Value Creation Garden City, NY, July 11, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today reported that Pharmaloz Manufacturing, Inc. (“PMI”), its wholly-owned subsidiary, is projecting significant re

GlobeNewswire 6 months ago

PRPH
-5.39%

Performance Overview

Return	PRPH	S&P 500
YTD	-15.90%	-1.08%
1-Year	-87.64%	+22.14%
3-Year	-91.08%	+25.41%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

ProPhase Labs, Inc. (PRPH)

ProPhase Labs Secures Global Private Equity Backing, Nears Major Lozenge Deal, Adds Seasoned Industry Expert, and Plans Significant Cost-Cutting Measures

Impact BioMedical Inc. Issues Shareholder Letter Highlighting Recent Achievements and Strategic Vision

ProPhase Labs Inc (PRPH) Q3 2024 Earnings Call Highlights: Strategic Launches and Financial ...

Diamond Equity Research Releases Update Note on ProPhase Labs Inc. (NASDAQ: PRPH)

ProPhase Labs, Inc. (PRPH) Reports Q3 Loss, Tops Revenue Estimates

ProPhase Labs Announces Financial Results for the Three Months Ended September 30, 2024

ProPhase Labs Announces Closing of Public Offering of Common Stock

ProPhase Labs Inc. to Present Third Quarter 2024 Financial Results on November 13, 2024

Top Midday Decliners

ProPhase Labs Announces Pricing of Public Offering of Common Stock

ProPhase Labs Announces Proposed Public Offering of Common Stock

ProPhase Labs Launches DNA Complete®: Transforming Direct-to-Consumer Genetic Testing for Health, Wellness, and Enhanced Ancestry

ProPhase Labs to Present at the 2024 ThinkEquity Conference

ProPhase Labs Announces Positive Updates on Strategic Initiatives Company Anticipates Multiple Liquidity Events in H1 2025

Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing

ProPhase Labs to Present at August 20th Virtual Investor Summit Microcap Event

ProPhase Labs Announces Financial Results for the Three Months Ended June 30, 2024

ProPhase Labs Announces Collaboration with Forward Healthcare Consultants to Aid in the Commercialization of its Billion Dollar Potential BE-Smart Esophageal Cancer Test

PROPHASE LABS INC. TO PRESENT SECOND QUARTER 2024 FINANCIAL RESULTS ON AUGUST 14

ProPhase Labs Announces Update on Pharmaloz Manufacturing, Inc. Progress

Performance Overview